Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $24.06 USD
Change Today -1.05 / -4.18%
Volume 1.3M
SGNT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Jonathon M. Singer

Chief Financial Officer and Executive Vice President, Sagent Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

51$804,524
As of Fiscal Year 2014

Background*

Mr. Jonathon M. Singer has been the Chief Financial Officer at Sagent Pharmaceuticals Inc. since September 2011 and its Executive Vice President since March 2012. Mr. Singer responsible for Sagent's finance and accounting functions. He has more than 26 years of finance experience with publicly-traded companies. He served as Senior Vice President, Treasurer, Secretary and Chief Financial Officer of Landauer Inc., from October 16, 2006 to September 9, 2011 and also served ...

Read Full Background

Corporate Headquarters*

1901 North Roselle Road
Schaumburg, Illinois 60195

United States

Phone: 847-908-1600
Fax: 847-908-1601

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

MA
Northwestern University
BBA
Miami University

Other Affiliations*

Annual Compensation*

Salary$344,793
Total Annual Compensation$344,793

Stock Options*

Restricted Stock Awards$119,992
All Other Compensation$8,824
Exercisable Options48,931
Exercisable Options Value$247,103
Unexercisable Options39,533
Unexercisable Options Value$221,322
Total Value of Options$468,424
Total Number of Options88,464

Total Compensation*

Total Annual Cash Compensation$560,493
Total Short Term Compensation$344,793
Other Long Term Compensation$128,816
Total Calculated Compensation$804,524
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $24.06 USD -1.05

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Friedhelm Blobel Ph.D.Chief Executive Officer, President, Executive Director and Member of Business Development Committee
SciClone Pharmaceuticals, Inc.
$566.5K
Yongfeng Zhang Ph.D.Chief Executive Officer, Chief Science Officer and Director
Amphastar Pharmaceuticals, Inc.
$1.4M
Aijaz Tobaccowalla Managing Director, Director, Member of Board Administrative & Share Transfer Committee, Member of Nomination & Remuneration Committee, Member of Corporate Social Responsibility Committee and Member of Audit Committee
Pfizer Limited
52.4M
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
$440.2K
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
$814.6K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.